USA flag logo/image

An Official Website of the United States Government

VESTAR RESEARCH INC.

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
3113
Program Year/Program:
1985 / SBIR
Agency Tracking Number:
3113
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Vestar, Inc.
650 Cliffside Drive San Dimas, CA 91773
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1985
Title: VESTAR RESEARCH INC.
Agency: HHS
Contract: N/A
Award Amount: $49,019.00
 

Abstract:

VESTAR RESEARCH INC. PROPOSES TO DEVELOP PHOSPHOLIPID VESICLE FORMULATIONS (LIPOSOMES) FOR INCORPORATION OF POORLY SOLUBLE AND/OR UNSTABLE ANTICANCER DRUGS INTO AQUEOUS MEDIA ACCEPTABLE FOR INTRAVENOUS USE. THIS METHODOLOGY WILL ENABLE US TO PREPARE AQUEOUS SUSPENSIONS OF ANTITUMOR AGENTS AT CONCENTRATIONS SUFFICIENT FOR THERAPEUTIC STUDIES. THIS IS SIGNIFICANT BECAUSE IT WILL OVERCOME THE SOLUBILITY AND STABILITY LIMITATIONS OF MANY INVESTIGATIONAL SUB-STANCES WITH IMPORTANT ANTITUMOR ACTIVITY. WE WILL OVERCOME THE FORMULATION PROBLEMS ASSOCIATED WITH THESE AGENTS BY DIRECTLY INCORPORATING THEM INTO THE MEMBRANE BILAYERS OF PHOSPHOLIPID VESICLES, THUS MINIMIZING ANY EXPOSURE TO AQUEOUS MEDIA. WE WILL DEMONSTRATE THAT THE MILD CONDITIONS USED FOR THIS METHODOLOGY WILL NOT ALTER THE CHEMICAL STABILITY OF THE FORMULATED DRUG WHILE ATTAINING THE GOAL OF A CONCENTRATED AQUEOUS PREPARATION. THE TECHNOLOGIES TO BE EMPLOYED FOR ACHIEVING THE STATED OBJECTIVES HAVE BEEN DEVELOPED AT VESTAR AND HAVE BEEN PROVEN TO SIGNIFICANTLY PROMOTE THE ACCUMULATION OF VESICLE ASSOCIATED AGENTS IN TUMOR TISSUE. THE PHASE II EFFORT WILL BUILD ON THE RESULTS OF THE PROPOSED WORK BY DEMONSTRATING THE ABILITY OF OUR VESICLE FORMULATIONS TO INCREASE THE LEVELS OF THERAPEUTIC AGENTS DELIVERED TO NEOPLASTIC TISSUE AND THUS ENHANCE ANTITUMOR ACTIVITY. FOR MOST COMPOUNDS IT SHOULD BE POSSIBLE TO ACCOMPLISH THIS WITHOUT INCREASING, AND MOST PROBABLY DECREASING, SYSTEMIC TOXICITY. THEREFORE, VESICLE PREPARATIONS OF POORLY SOLUBLE AND/OR UNSTABLE SUBSTANCES HAVE THE CLEAR POTENTIAL FOR SIGNIFICANTLY

Principal Investigator:

Richard t. proffitt
PRINCIPAL INVESTIGATOR
8187926101

Business Contact:

Small Business Information at Submission:

Vestar Research Inc.
939 East Walnut Street Pasadena, CA 91106

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No